Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYSLTR1 | Q9Y271 | 14/20 | 0.48 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.47 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.47 |
| ▸ | CYSLTR2 | Q9NS75 | 8/20 | 0.46 |
| ▸ | PPARG | P37231 | 1/20 | 0.43 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9757103 | 0.91 | CYSLTR1 (0.49) | CYSLTR1FFAR1AKR1B1CYSLTR2PPARG | |
| SCHEMBL9757042 | 0.82 | CYSLTR1 (0.52) | CYSLTR1FFAR1AKR1B1CYSLTR2GPBAR1 | |
| SCHEMBL9636824 | 0.81 | CYSLTR1 (0.45) | CYSLTR1FFAR1AKR1B1CYSLTR2GPBAR1 | |
| SCHEMBL9760905 | 0.80 | CYSLTR1 (0.44) | CYSLTR1FFAR1AKR1B1CYSLTR2GPBAR1 | |
| SCHEMBL9760316 | 0.80 | CYSLTR1 (0.54) | CYSLTR1FFAR1AKR1B1CYSLTR2GPBAR1 | |
| SCHEMBL9757410 | 0.79 | CYSLTR1 (0.50) | CYSLTR1FFAR1AKR1B1CYSLTR2PPARG | |
| SCHEMBL9757153 | 0.79 | GPBAR1 (0.52) | CYSLTR1CYSLTR2GPBAR1 | |
| SCHEMBL9757216 | 0.76 | CYSLTR1 (0.38) | CYSLTR1CYSLTR2 | |
| SCHEMBL9757063 | 0.76 | CYSLTR1 (0.47) | CYSLTR1CYSLTR2GPBAR1 | |
| SCHEMBL9757127 | 0.76 | CYSLTR1 (0.46) | CYSLTR1CYSLTR2PPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5041453-A | Quinolinyl-benzoheterobicyclic derivatives as antagonists of leukotriene D4 | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1991-08-20 | — | — | US | disclosed |